Spironolactone in the Treatment of Heart Failure

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 743 participants.

Also called NCT04727073

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 743 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04727073
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Austria, France, Germany, Netherlands, Serbia (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT04727073. Randomized; double masking; primary purpose treatment. Start 2018-11-01 (actual); primary completion 2024-10-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Spironolactone in the Treatment of Heart Failure
Acronym
SPIRIT-HF
Condition
Heart Failure with Mid-range Ejection Fraction
Intervention (Drug)
Experimental: Spironolactone
Intervention (Drug)
Placebo Comparator
Lead sponsor
Charite University, Berlin, Germany (class: other)
Collaborator
Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) (class: other)
Collaborator
Echo Core Lab Berlin (class: not stated)
Collaborator
University of Göttingen (class: other)
Collaborator
University Medicine Greifswald (class: other)
Collaborator
Ludwig-Maximilians - University of Munich (class: other)
Collaborator
Institute for Cardiovascular Computer-assisted Medicine, Charité (class: not stated)
Collaborator
Coordinating Centre for Clinical Trials, Charité (class: not stated)

Record details

Record id
cardio:ct-nct04727073
Content hash
e223626ebc4b3fe2a5249367854994ef59b9d40a309e3a9a735af431ce089416